Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit?
Victor
V
Serebruany
Shinya
S
Goto
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000244:Adenosine Diphosphate; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D009853:Omeprazole / Q000627:therapeutic use*; D000077402:Pantoprazole; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D015607:Stents; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D000244:Adenosine Diphosphate; D000077144:Clopidogrel; D000077402:Pantoprazole; D009853:Omeprazole; D013988:Ticlopidine; D001241:Aspirin